Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 1, pp 53–59

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

  • Jun-ichi Kitagawa
  • Takeshi Hara
  • Hisashi Tsurumi
  • Naoe Goto
  • Nobuhiro Kanemura
  • Takeshi Yoshikawa
  • Senji Kasahara
  • Toshiki Yamada
  • Michio Sawada
  • Takeshi Takahashi
  • Masahito Shimizu
  • Tsuyoshi Takami
  • Hisataka Moriwaki
Original Paper

Abstract

Purpose

The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

Patients and methods

We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.

Keywords

Peripheral T-cell lymphoma (PTCL) Soluble interleukin-2 receptor (sIL-2R) Prognostic analysis 

References

  1. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921–1925PubMedGoogle Scholar
  2. Cantrell DA, Smith KA (1983) Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 158:1895–1911. doi:10.1084/jem.158.6.1895 PubMedCrossRefGoogle Scholar
  3. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
  4. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479. doi:10.1182/blood-2003-09-3080 PubMedCrossRefGoogle Scholar
  5. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82PubMedGoogle Scholar
  6. Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M et al (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131:73–79. doi:10.1007/s00432-004-0600-9 PubMedCrossRefGoogle Scholar
  7. Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77:217–225. doi:10.1111/j.1600-0609.2006.00702.x PubMedCrossRefGoogle Scholar
  8. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:1131–1137PubMedGoogle Scholar
  9. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M et al (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64:257–261. doi:10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2PubMedCrossRefGoogle Scholar
  10. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMedGoogle Scholar
  11. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534. doi:10.1056/NEJM199708213370804 PubMedCrossRefGoogle Scholar
  12. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF et al (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 31:351–357PubMedGoogle Scholar
  13. Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268. doi:10.1002/mpo.2950220410 PubMedCrossRefGoogle Scholar
  14. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood 94:3541–3550PubMedGoogle Scholar
  15. Niitsu N, Okamoto M, Okabe-Kado J, Takagi T, Yoshida T, Aoki S et al (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202–1210. doi:10.1182/blood.V97.5.1202 PubMedCrossRefGoogle Scholar
  16. Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U et al (2003) Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin’s lymphoma. Leukemia 17:196–202. doi:10.1038/sj.leu.2402699 PubMedCrossRefGoogle Scholar
  17. Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K et al (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Br J Haematol 93:45–52. doi:10.1046/j.1365-2141.1996.4641003.x PubMedCrossRefGoogle Scholar
  18. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186–194PubMedGoogle Scholar
  19. Robb RJ (1982) Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res 1:37–43PubMedGoogle Scholar
  20. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177PubMedGoogle Scholar
  21. Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma. Blood 94:3334–3339PubMedGoogle Scholar
  22. Sasaki K, Niitsu N (2000) Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 65:195–202. doi:10.1034/j.1600-0609.2000.065003195.x PubMedCrossRefGoogle Scholar
  23. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H et al (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi:10.1034/j.1600-0609.2002.01654.x PubMedCrossRefGoogle Scholar
  24. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429PubMedGoogle Scholar
  25. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E et al (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin’s lymphoma. Br J Haematol 88:770–777. doi:10.1111/j.1365-2141.1994.tb05116.x PubMedCrossRefGoogle Scholar
  26. Takagi T, Oguro M (1987) (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154. doi:10.1007/BF00253970 PubMedCrossRefGoogle Scholar
  27. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402 CrossRefGoogle Scholar
  28. Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi:10.1007/s00432-003-0508-9 PubMedCrossRefGoogle Scholar
  29. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M et al (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114. doi:10.1002/hon.815 PubMedCrossRefGoogle Scholar
  30. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M et al (1996) Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132:42–47. doi:10.1001/archderm.132.1.42 PubMedCrossRefGoogle Scholar
  31. Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L et al (1997) Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 82:171–177PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Jun-ichi Kitagawa
    • 1
  • Takeshi Hara
    • 1
  • Hisashi Tsurumi
    • 1
  • Naoe Goto
    • 1
  • Nobuhiro Kanemura
    • 1
  • Takeshi Yoshikawa
    • 2
  • Senji Kasahara
    • 1
  • Toshiki Yamada
    • 1
  • Michio Sawada
    • 1
  • Takeshi Takahashi
    • 2
  • Masahito Shimizu
    • 1
  • Tsuyoshi Takami
    • 3
  • Hisataka Moriwaki
    • 1
  1. 1.First Department of Internal MedicineGifu University Graduate School of MedicineGifuJapan
  2. 2.Division of HematologyGifu Municipal HospitalGifuJapan
  3. 3.Department of ImmunopathologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations